Cytokeratin 8/18 expression indicates a poor prognosis in squamous cell carcinomas of the oral cavity
© Fillies et al; licensee BioMed Central Ltd. 2006
Received: 11 May 2005
Accepted: 13 January 2006
Published: 13 January 2006
Intermediary filaments are involved in cell motility and cancer progression. In a variety of organs, the expression of distinct intermediary filaments are associated with patient prognosis. In this study, we seeked to define the prognostic potential of cytokeratin and vimentin expression patterns in squamous cell carcinomas (SCC's) of the oral cavity.
308 patients with histologically proven and surgically treated squamous cell carcinomas of the oral cavity were investigated for the immunohistochemical expression of a variety of intermediary filaments including high- and low-molecular weight cytokeratins (Ck's), such as Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck 19 and vimentin, using the tissue microarray technique. Correlations between clinical features and the expression of Cytokeratins and vimentin were evaluated statistically by Kaplan-Meier curves and multivariate Cox regression analysis.
The expression of Ck 8/18 and Ck 19 were overall significantly correlated with a poor clinical prognosis (Ck 8/18 p = 0.04; Ck19 p < 0.01). These findings could also be reproduced for Ck 8/18 in primary nodal-negative SCC's and held true in multivariate-analysis. No significant correlation with patient prognosis could be found for the expression of the other cytokeratins and for vimentin.
The expression of Ck 8/18 in SCC's of the oral cavity is an independent prognostic marker and indicates a decreased overall and progression free survival. These results provide an extended knowledge about the role of intermediary filament expression patterns in SCC's.
Intermediary filaments, like cytokeratins are essential intracellular components, underlying or reflecting distinct cellular properties and differentiation stages in epithelial organs. The proteins of the cytokeratin family are epithelium specific expressed  as low and high-molecular weight, resp. acid and basic polypeptides. Squamous, stratified epithelium is usually characterized by the expression of CK 5, which is found mainly in the basal cell layers and Ck 5 is associated with the proliferative potential of these cells [2, 3]. The intermediary cell layers show an additional expression of Ck's 1 and 10, which are regarded as signs of cellular differentiation . In contrast, glandular epithelia reveal the expression of low-molecular weight cytokeratins Ck's 8/18 and 19 as typical features – expression pattern of Ck 8/18 is rather uncommon in mature squamous epithelium. Ck 19 expressed heterogeneously in the basal cell layers of stratified squamous epithelium [2, 3]. Suprabasal expression of Ck 19 seems to be correlated with premalignant transformation in oral epithelium . The expression of vimentin is mainly regarded as sign of a mesenchymal differentiation. However, vimentin-positively has repeatedly reported in various carcinomas and was interpreted as sign of an epithelial-mesenchymal transition, indicating an increased metastatic potential [5–9].
Recently, it could be shown that the induction of Ck 8/18 expression in non-malignant buccal mucosa cells resulted in a significant change of phenotypic characteristics after Ck 8/18 transfection . These changes included an increased cellular motility, which might give first hints for an increased tumour aggressiveness and poor patient prognosis. However, these findings have not been transferred on a clinical level, yet. Therefore, the significance of these findings in a clinical context, especially in regard to the prognostic importance is unclear.
It was therefore the aim of this study to evaluate the expression of intermediary filaments in SCC's in relation to clinico-pathological features, especially for prognostic purposes by the use of tissue micro arrays and immunohistochemistry.
Patients with histologically proven squamous cell carcinoma of the oral floor treated surgically were eligible for the study. All patients underwent surgical treatment including radical resection of the whole tumour with a free histopathological margin of at least 4 mm from the tumour borders. Selective neck dissection of Level I, II, III and V was performed in case of suspect results in preoperative tumourstaging by computertomography or sonography examination or in case of tumour size over 2 cm, bilateral selective neck dissection was performed when the tumour spread the midline (according to the recommendation of Robins et al. 2002 ). Radiotherapy was performed when lymph node metastases were detected histologically. All tumours were classified postsurgically according to the TNM system 6th eds. UICC 2002 .
Antibodies, company, clone, pre-treatment and dilution of used antibodies.
DAKO, Glostrup, Denmark
Autoclave 10 min
1 : 80
Dianova, Hamburg, Germany
Autoclave 10 min, citrate buffer
1 : 40
Novocastra, Newcastle, UK
Steamer 30 min, citrate buffer
1 : 150
DAKO, Glostrup, Denmark
Steamer 30 min, citrate buffer
1 : 400
Dianova Hamburg, Germany
Steamer 30 min, citrate buffer
1 : 50
Quartett GmbH, Berlin, Germany
Steamer 30 min, citrate buffer
1 : 80
Ventana Inc., Tucson, USA
Steamer 30 min, citrate buffer
1 : 1000
For tissue micro array (TMA) construction, two punch biopsies with a diameter of 0.6 mm from each donor block were taken and transferred into the new acceptor block. TMA construction was performed by using a special tissue micro array instrument (Beecher Instruments, New Jersey, USA), according to standard protocols [13, 14].
Immunohistochemistry was performed on 4-μm-thick TMA sections. After deparaffinization and rehydration, endogenous peroxidase activity was blocked for 30 minutes in methanol containing 0.3% hydrogen peroxide. After antigen retrieval, a cooling-off period of 20 minutes preceded the incubation of the primary antibody. Thereafter, the catalyzed signal amplification system (DAKO, Glostrup, Denmark) was used for Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck 19 and vimentin staining according to the manufacturer's instructions.
All antibodies were detected by a standard avidin-biotin complex method with a biotinylated rabbit anti-mouse antibody (DAKO) and an avidin-biotin complex (DAKO). The stainings were developed with diaminobenzidine or alternatively using LSAB/AP (DAKO). Before the slides were mounted, all sections were counterstained for 45 seconds with hematoxylin and dehydrated in alcohol and xylene. Appropriate negative controls (obtained by omission of the primary antibody) and positive controls were used throughout.
The expression of Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck 19 and vimentin were determined independently by two pathologists (HB and JP). Both pathologists determined the percentage of positive cells in each core.
The percentage was classified for Cytokeratin 19 in 3 groups (0 % no Expression, 1:1–50% moderate expression, 2 >50% high expression) and Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14 and vimentin in two groups (0: no Expression, 1: ≥1% positive expression). The mean percentage value of the two cores representing one tumour and were used for further evaluation.
The TNM-stage, the histological differentiation and the expression of Ck 5/6, Ck 8/18, Ck 1, CK 10, Ck 14, Ck 19 and vimentin were related to the duration of the progression-free and the overall survival. The measurement of time started from the date of surgery to the date of histologically proven recurrent or metastatic carcinoma or disease related death, respectively. Patients who died from intercurrent disease during the trial were censored at the date of death. Patients lost to follow-up were censored at the date of the last examination.
Correlations between clinical features and the expression of cytokeratins were evaluated statistically by chi-square tests. The overall survival curves were constructed according to Kaplan and Meier . The Log-Rank test was used to assess differences between groups and the multivariate survival analysis was performed with Cox regression , a p-value < 0.05 was considered to be significant.
Tumour patient cases in this study
58 years (range 31 – 90 years)
240 men, 68 women
64 months (range 4 – 181 months)
135 T1 tumours
125 T2 tumours
15 T3 tumours
33 T2 tumours
212 N0 lymph node negative
57 N1 lymph node positive carcinoma
39 N2 lymph node positive carcinoma
54 well differentiated tumours (G1)
214 moderately differentiated tumours (G2)
40 weakly differentiated tumours (G3)
On average 90 % of all cores could be evaluated for the expression of intermediate filaments.
Immunohistochemical examination showed that Ck 8/18, Ck 5/6, Ck 1, CK 10, Ck 14, Ck 19 and vimentin reactivity was confined homogeneously to the cytoplasma of neoplastic cells. The expression levels did not differ significantly for the vast majority of the cases between the two tumour cores representing one case, indicating a rather homogeneous expression. No correlation was found between Ck 1, Ck 5/6, Ck 10, Ck 14, vimentin and the survival prognosis.
Expression profile of cytokeratins
Chi-square Test of Ck 5–6 and Ck 14
Node status P value
Tumour size P value
All carcinomas with an expression of Ck 8/18 and Ck 19 were reviewed and re-evaluated on whole sections. This was done in order to exclude the possibility of a misinterpretation and misclassification of dedifferentiated salivary gland carcinomas as poorly differentiated SCC's. However, in all these tumours the diagnosis of a primary salivary gland carcinoma could be ruled out.
Multivariate analysis of the time of survival in relation to the Cytokeratins expression and other prognostic factors
Intermediate filaments are central components of the intracellular skeleton. The expression of distinct intermediate filament proteins is tissue-specific and almost highly conserved during carcinogenesis. Intermediate filaments are interpreted as mere bystanders and markers of distinct intracellular, cell-specific regulation mechanisms. Several studies associated changes in intermediate filament expression with an altered cellular behaviour [17, 18].
The expression of high molecular weight cytokeratins, especially Ck 5 is a hallmark of squamous epithelium and is predominantly seen in the basal layers of stratified epithelium [2, 19]. This cell layer is regarded as the anatomical localization of tissue specific stem/progenitor cells. Stem cells of stratified epithelium have been repeatedly described as the major cellular targets for cancer causing mutations and therefore might give in a long term rise to the development of SCC's. In the context of the existing literature it seems logical that SCC's retain and are phenotypically characterized by the expression of Ck 5. Adult healthy non-keratinizing stratified squamous epithelium of the upper aerodigestive tract express Ck 19 in basal layers but normally do not express Ck 8/18 . Typical glandular cytokeratin Ck 8/18 are normally not expressed in SCC's [2, 4]. On the other hand, Ck 8 and 18 is expressed in fetal buccal mucosa and tongue epithelium till 27 weeks of gestation .
Our study shows in a series of more than 300, uniformly treated, primary SCC's of the oral cavity that the expression of glandular cytokeratins such as Ck 8, 18 and 19, pinpoints a significant subgroup of SCC's. These carcinomas were associated with a poor prognosis, independently of the primary, preoperative lymph node status. It is important to stress that this held also true in multivariate analysis. This might be surprising on a first glance, since recent other clinico-pathological studies in SCC's of the oral cavity, especially with the focus on Ck 19 revealed inhomogeneous results [21–24]. This might on the one hand be due to significantly lower numbers of investigated tumour samples, and on the other hand caused by different techniques for the determination for the expression of cytokeratins 8/18 and 19 on the RNA and protein level. However, similar results to our findings have also been reported for skin carcinomas. Nevertheless, recent cell culture and studies with chemical carcinogens strongly support our results and revealed an important role of CK 8/18 in various steps of the pathogenesis and progression of SCC's. A spontaneous induction of Ck's 8 and 18 expression could be shown in SV40T-immortalized buccal mucosa cells, in tobacco induced leukoplakias and after introduction of v-H-Ras in epidermal mouse keratinocytes . The transfection of buccal mucosa cells with a vector for Ck 8/18 resulted additionally in a significantly altered cellular morphology and increased cell motility – features associated with or being prerequisites for invasive tumour behaviour . This was in line with previous experiments in melanoma cells . The involvement of Ck 8/18 in SCC progression could further be demonstrated in chemically induced SCC's in the mouse skin. Whereas SCC's in mouse epidermis were Ck 8/18 positive, non-invasive papillomas did not show this feature. However, the underlying disturbed intra- and extra cellular regulation mechanisms have been characterized not in detail yet. A central role for TGF-alpha via the Epidermal Growth Factor Receptor (EGFR) has been postulated [27, 28]. In contrast, the induction of Ck 8/18 expression in a similar experimental setting has also been described for TGF-alpha deficient mice, with putative involvement of H-Ras . In consequence, multiple pathways in the regulation of Ck 8/18 are conceivably existing.
In general, cytokeratin expression patterns are highly-conserved. The above mentioned data from the literature showed that any change in the intermediate filament expression pattern reflects or underlies changes in substantial cellular properties. Strong homologies could also be shown in other carcinomas. In primary breast cancer, this could be demonstrated with different approaches. Down-regulated expression of cytokeratin Ck 8/18 was associated with increased metastatic properties and poor prognosis in breast cancer . The expression of Ck 5 in a small subset of invasive breast cancers was in contrast associated with a poor prognosis .
Interestingly, the expression of vimentin, alone or in combination with Ck 8/18 and 19, was not associated with poor prognosis or higher tumour stages. A multitude of studies gave evidence that the expression of vimentin in carcinomas has to be interpreted as a sign of an epithelial-mesenchymal transition, associated with high tumour aggressiveness [9, 32]. This association remains questionable, since the expression of vimentin has already been described in non-invasive premalignant lesions of squamous epithelium and cultured keratinocytes.
Finally, from a clinical point of view, our results show that the determination of the Cytokeratin 8–18 and 19-expression in SCC of the oral cavity harbours a significant prognostic potential. Our results seem to define subgroups of high-risk patients who might benefit from more intensive therapy or new therapeutic strategies like Cytokeratin 19 antibodies . For human ovarian adenocarcinoma cells it could be shown that cytokeratins 18 could sensitize these cells to cisplatin . These results demonstrate that modulating the expression of an intermediate filament protein results in sensitization to chemotherapeutic drugs. The subgroup of ck 8–18 positive squamous cell carcinoma may have a benefit by chemotherapy with cisplatin. Further investigations are necessary to determine the clinical impact of these hypotheses.
In conclusion, our results in a series of 308 primary, previously untreated SCC's of the oral cavity showed an important prognostic impact for the expression of glandular, simple cytokeratins in SCC's. Further studies have to unravel the underlying regulatory changes in order to allow the definition of specific therapies of these high risk cancer patients.
- Moll R, Franke WW, Schiller DL, Geiger B, Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982, 31 (1): 11-24. 10.1016/0092-8674(82)90400-7.View ArticlePubMed
- Presland RB, Jurevic RJ: Making sense of the epithelial barrier: what molecular biology and genetics tell us about the functions of oral mucosal and epidermal tissues. J Dent Educ. 2002, 66 (4): 564-74.PubMed
- van der Velden LA, Manni JJ, Ramaekers FC, Kuijpers W: Expression of intermediate filament proteins in benign lesions of the oral mucosa. Eur Arch Otorhinolaryngol. 1999, 256 (10): 514-9. 10.1007/s004050050202.View ArticlePubMed
- Lindberg K, Rheinwald JG: Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Am J Pathol. 1989, 134 (1): 89-98.PubMed CentralPubMed
- Vernon AE, LaBonne C: Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr Biol. 14 (17): R719-21. 10.1016/j.cub.2004.08.048. 2004 Sep 7
- Santini D, Ceccarelli C, Taffurelli M, Pileri S, Marrano D: Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol. 1996, 179 (4): 386-91. 10.1002/(SICI)1096-9896(199608)179:4<386::AID-PATH631>3.0.CO;2-V.View ArticlePubMed
- Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M: Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol. 1990, 136 (1): 219-27.PubMed CentralPubMed
- Ramaekers FC, Haag D, Kant A, Moesker O, Jap PH, Vooijs GP: Coexpression of keratin- and vimentin-type intermediate filaments in human metastatic carcinoma cells. Proc Natl Acad Sci U S A. 1983, 80 (9): 2618-22.PubMed CentralView ArticlePubMed
- de Araujo VC, Pinto Junior DS, de Sousa SO, Nunes FD, de Araujo NS: Vimentin in oral squamous cell carcinoma. Eur Arch Otorhinolaryngol. 1993, 250 (2): 105-9.View ArticlePubMed
- Raul U, Sawant S, Dange P, Kalraiya R, Ingle A, Vaidya M: Implications of cytokeratin 8/18 filament formation in stratified epithelial cells: induction of transformed phenotype. Int J Cancer. 111 (5): 662-8. 10.1002/ijc.20349. 2004 Sep 20
- Robbins KT, Clayman G, Levine PA, Medina J, Sessions R, Shaha A, Som P, Wolf GT, American Head and Neck Society; American Academy of Otolaryngology – Head and Neck Surgery: Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. Arch Otolaryngol Head Neck Surg. 2002, 128 (7): 751-8.View ArticlePubMed
- Wittekind C, Greene FL, Hutter RVP, Klimpfinger M, Sobin LH: TNM Atlas. 2005, Springer Verlag Heidelberg, 5View Article
- Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med. 1998, 4: 844-847. 10.1038/nm0798-844.View ArticlePubMed
- Packeisen J, Buerger H, Krech R, Boecker W: Tissue microarrays: a new approach for quality control in immunohistochemistry. J Clin Pathol. 2002, 55 (8): 613-5. 10.1136/jcp.55.8.613.PubMed CentralView ArticlePubMed
- Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Ass. 1958, 53: 457-481.View Article
- Cox DR: Regression models and life-tables. JR Stat Soc [B]. 1972, 34: 187-202.
- Watanabe S, Ichikawa E, Takahashi H, Otsuka F: Changes of cytokeratin and involucrin expression in squamous cell carcinomas of the skin during progression to malignancy. Br J Dermatol. 1995, 132 (5): 730-9.View ArticlePubMed
- Morgan PR, Su L: Intermediate filaments in oral neoplasia. I. Oral cancer and epithelial dysplasia. Eur J Cancer B Oral Oncol. 1994, 30B (3): 160-6. 10.1016/0964-1955(94)90085-X. ReviewView ArticlePubMed
- Chu PG, Weiss LM: Keratin expression in human tissues and neoplasms. Histopathology. 2002, 40 (5): 403-39. 10.1046/j.1365-2559.2002.01387.x.View ArticlePubMed
- Vaidya MM, Sawant SS, Borges AM, Naresh NK, Purandare MC, Bhisey AN: Cytokeratin expression in human fetal tongue and buccal mucosa. J Biosci. 2000, 25 (3): 235-42.View ArticlePubMed
- Crowe DL, Milo GE, Shuler CF: Keratin 19 downregulation by oral squamous cell carcinoma lines increases invasive potential. J Dent Res. 1999, 78 (6): 1256-63.View ArticlePubMed
- Depondt J, Shabana AH, Sawaf H, Gehanno P, Forest N: Cytokeratin alterations as diagnostic and prognostic markers of oral and pharyngeal carcinomas. A prospective study. Eur J Oral Sci. 1999, 107 (6): 442-54. 10.1046/j.0909-8836.1999.eos107605.x.View ArticlePubMed
- Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR: Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer. 1996, 73 (4): 531-8.View Article
- Janot F, Klijanienko J, Russo A, Mamet JP, de Braud F, El-Naggar AK, Pignon JP, Luboinski B, Cvitkovic E: Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer. 1996, 73 (4): 531-8.PubMed CentralView ArticlePubMed
- Hansson A, Bloor BK, Sarang Z, Haig Y, Morgan PR, Stark HJ, Fusenig NE, Ekstrand J, Grafstrom RC: Analysis of proliferation, apoptosis and keratin expression in cultured normal and immortalized human buccal keratinocytes. Eur J Oral Sci. 2003, 111 (1): 34-41. 10.1034/j.1600-0722.2003.00010.x.View ArticlePubMed
- Chu YW, Seftor EA, Romer LH, Hendrix MJ: Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol. 1996, 148 (1): 63-9.PubMed CentralPubMed
- Inada H, Izawa I, Nishizawa M, Fujita E, Kiyono T, Takahashi T, Momoi T, Inagaki M: Keratin attenuates tumor necrosis factor-induced cytotoxicity through association with TRADD. J Cell Biol. 155 (3): 415-26. 10.1083/jcb.200103078. Epub 2001 Oct 29
- Gilbert S, Loranger A, Daigle N, Marceau N: Simple epithelium keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The protection occurs through a receptor-targeting modulation. J Cell Biol. 154 (4): 763-73. 10.1083/jcb.200102130. 2001 Aug 20
- Oshima RG, Baribault H, Caulin C: Oncogenic regulation and function of keratins 8 and 18. Cancer Metastasis Rev. 1996, 15 (4): 445-71. 10.1007/BF00054012.View ArticlePubMed
- Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K: Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res. 10 (8): 2670-4. 10.1158/1078-0432.CCR-03-0114. 2004 Apr 15
- Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004, 203 (2): 661-71. 10.1002/path.1559.View ArticlePubMed
- Schaafsma HE, Van Der Velden LA, Manni JJ, Peters H, Link M, Rutter DJ, Ramaekers FC: Increased expression of cytokeratins 8, 18 and vimentin in the invasion front of mucosal squamous cell carcinoma. J Pathol. 1993, 170 (1): 77-86. 10.1002/path.1711700113.View ArticlePubMed
- Yuan CC, Huang HC, Tsai LC, Ng HT, Huang TS: Cytokeratin-19 associated with apoptosis and chemosensitivity in human cervical cancer cells. Apoptosis. 1997, 2 (1): 101-5. 10.1023/A:1026448027870.View ArticlePubMed
- Parekh HK, Simpkins H: The differential expression of cytokeratin 18 in cisplatin-sensitive and -resistant human ovarian adenocarcinoma cells and its association with drug sensitivity. Cancer Res. 55 (22): 5203-6. 1995 Nov 15
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/10/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.